BioNTech SE: Business Overview, Financials & Competitive Analysis

BioNTech SE Overview

BioNTech is pursuing a strategic transformation to become a diversified, multi-product, global biopharmaceutical company addressing high unmet medical needs of cancer patients worldwide by 2030. Q1 2026 revenues declined 35.5% year-over-year to €118.1 million due to lower COVID-19 vaccine demand, while the company emphasizes a strategic pivot to late-stage oncology with multiple pivotal trial readouts expected through 2030.

Strategic Profile

BioNTech's revenue-generating COVID-19 vaccine business and strategic partnership with BMS supported a strong financial position throughout 2025. The company is progressing key programs into pivotal stage while executing combination therapy studies, accelerating pivotal trial execution, and building tumor indication-specific portfolios to execute its first oncology launches. The company held approximately €17.2 billion in cash, cash equivalents and security investments as of December 31, 2025, providing substantial resources to fund its oncology-focused pipeline.

Competitive Landscape

BioNTech competes in a dynamic COVID-19 vaccine market and is navigating transition away from multi-year contracts in Europe while defending market share. In oncology, BioNTech competes against established biopharmaceutical companies developing personalized cancer vaccines and immunotherapies including Merck, Bristol Myers Squibb, and Moderna. The company has 50% gross profit sharing partnerships with Pfizer for Comirnaty and revenues from collaboration with BMS in 2026 expected to be in line with 2025.

Industry Context

BioNTech SE operates in Biotechnology.

Key facts

Founded: 2008 · Headquarters: Mainz, Germany · Employees: As of 2026-07-22, not specified in recent filings · Revenue: €2.0–2.3 billion guidance for full-year 2026; €118.1 million Q1 2026 actual; €2.87 billion full-year 2025 · Market cap: Approximately $27B–$30B (based on share price fluctuations)